Tue, Jul-19-16, 10:45
|
 |
Senior Member
Posts: 3,199
|
|
Plan: High protein, lower fat
Stats: 000/000/145
BF:276, 255 hi wts
Progress: 0%
Location: Michigan U.P., USA
|
|
Are these the ones he's referring to?
Quote:
The FDA has green-lighted three SGLT2 inhibitors:
Canagliflozin (Invokana), approved March, 2013
Dapagliflozin (Farxiga), approved January, 2014
Empagliflozin (Jardiance), approved August, 2014
Most diabetes drugs target the liver, pancreas, or gut to improve insulin sensitivity, reduce insulin resistance, or stimulate insulin secretion.
But SGLT2 inhibitors work in a different way. They have no effect on insulin. Instead, they target the kidneys to block the reabsorption of sugar, increase sugar excretion, thereby reducing blood sugar levels. http://www.newsmax.com/Health/Headl...3/29/id/635154/
|
|